Saturday, July 25, 2020 10:33:46 AM
https://www.nasdaq.com/press-release/tonix-pharmaceuticals-holding-corp.-announces-rescheduling-of-special-meeting-of
RE;
Tonix Pharmaceuticals Holding Corp. Announces Rescheduling of Special Meeting of Stockholders
PUBLISHED
JUL 21, 2020 4:45PM EDT
NEW YORK, July 21, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company,
today announced that it is rescheduling the date of the Company’s Special Meeting of Stockholders (the “Special Meeting”) previously scheduled for Friday, June 26, 2020, to Friday, August 28, 2020, at 11:00 a.m., Eastern Time.
In connection with the change of the Special Meeting date, the record date for determining stockholders entitled to attend and vote at the Special Meeting has been changed to the close of business on July 15, 2020.
There are no changes to the proposals previously described in the Company’s proxy statement for the Special Meeting. The Company will be distributing a proxy statement, proxy card and notice of internet availability for the Special Meeting describing the proposals to be voted upon.
Stockholders who have previously sent in proxies, or voted by telephone or by Internet, may submit new proxies or vote by telephone or Internet in advance of the meeting on August 28, 2020 by one of the methods described in the proxy statement to be distributed.
If no further action is taken by a stockholders who previously sent in a proxy, or voted by telephone or by Internet, the stockholder’s previous elections shall remain in effect.
To attend the Special Meeting, stockholders will need to register at http://viewproxy.com/tonixpharma/2020vm and enter certain information, including their name and the control number found on the proxy card, voting instruction form, or notice of internet availability to be distributed to stockholders, by following the instructions available on the meeting website.
About Tonix Pharmaceuticals Holding Corp.
Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing small molecules and biologics to treat and prevent human disease and alleviate suffering.
Tonix’s portfolio is primarily composed of central nervous system (CNS) and immunology product candidates.
The immunology portfolio includes vaccines to prevent infectious diseases and biologics to address immunosuppression, cancer and autoimmune diseases.
The CNS portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. Tonix’s lead vaccine candidate, TNX-1800*,
is a live replicating vaccine based on the horsepox viral vector platform to protect against COVID-19, primarily by eliciting a T cell response. Tonix expects data from animal studies of TNX-1800 in the fourth quarter of this year.
TNX-801*, live horsepox virus vaccine for percutaneous administration, is in development to protect against smallpox and monkeypox and serves as the vector platform on which TNX-1800 is based.
Tonix is also developing TNX-2300*, a second live replicating vaccine candidate for the prevention of COVID-19, but using bovine parainfluenza as the vector.
Tonix’s lead CNS candidate, TNX-102 SL**, is in Phase 3 development for the management of fibromyalgia. The Company expects results from an unblinded interim analysis in September 2020 and topline data in the fourth quarter of 2020.
TNX-102 SL is also in development for agitation in Alzheimer’s disease and alcohol use disorder (AUD). The agitation in Alzheimer’s disease program is Phase 2 ready with FDA Fast Track designation, and the development program for AUD is in the pre-Investigational New Drug (IND) application stage.
Tonix‘s programs for treating addiction conditions also include TNX-1300* (T172R/G173Q double-mutant cocaine esterase 200 mg, i.v. solution), which is in Phase 2 development for the treatment of life-threatening cocaine intoxication and has FDA Breakthrough Therapy designation.
TNX-601 CR** (tianeptine oxalate controlled-release tablets) is another CNS program, currently in Phase 1 development as a daytime treatment for depression while TNX-1900**,
intranasal oxytocin, is in development as a non-addictive treatment for migraine and cranio-facial pain.
Tonix’s preclinical pipeline includes TNX-1600** (triple reuptake inhibitor) , a new molecular entity being developed as a treatment for PTSD; TNX-1500* (anti-CD154), a monoclonal antibody being developed to prevent and treat organ transplant rejection and autoimmune conditions;
and TNX-1700* (rTFF2), a biologic being developed to treat gastric and pancreatic cancers.
*TNX-1800, TNX-801, TNX-2300, TNX-1300, TNX-1500 and TNX-1700 are investigational new biologics and have not been approved for any indication.
**TNX-102 SL, TNX-601 CR, TNX-1600 and TNX-1900 are investigational new drugs and have not been approved for any indication.
This press release and further information about Tonix can be found at http://www.tonixpharma.com.
Contacts
Jessica Morris (corporate)Tonix Pharmaceuticalsinvestor.relations@tonixpharma.com(212) 688-9421
Travis Kruse (media)Russo Partnerstravis.kruse@russopartnersllc.com(212) 845-4272
Peter Vozzo (investors)Westwickepeter.vozzo@westwicke.com(443) 213-0505
Tonix2.jpg
Tonix Pharmaceuticals Holding Corp.
IN THIS STORY
Recent TNXP News
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/08/2024 09:01:36 PM
- Tonix Pharmaceuticals Announces Proposed Public Offering • GlobeNewswire Inc. • 07/08/2024 09:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/08/2024 12:05:24 PM
- Tonix Pharmaceuticals Reports Final Positive Pre-NDA Meeting with FDA for Tonmya™ for the Management of Fibromyalgia • GlobeNewswire Inc. • 07/08/2024 12:00:00 PM
- Tonix Pharmaceuticals Awarded Up to $34 Million U.S. Department of Defense Contract for Accelerated Development of Broad-Spectrum Antiviral Program • GlobeNewswire Inc. • 07/01/2024 12:00:00 PM
- Tonix Pharmaceuticals Announces Closing of $4.0 Million Public Offering • GlobeNewswire Inc. • 06/28/2024 08:05:00 PM
- Tonix Pharmaceuticals Announces Pricing of Approximately $4.0 Million Public Offering • GlobeNewswire Inc. • 06/27/2024 12:36:51 PM
- Tonix Pharmaceuticals Announces Proposed Public Offering • GlobeNewswire Inc. • 06/26/2024 08:40:16 PM
- Tonix Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement • GlobeNewswire Inc. • 06/26/2024 07:13:29 PM
- Tonix Pharmaceuticals Presents Vaccine Platform Data in Keynote Talk at the Vaccine Congress 2024 • GlobeNewswire Inc. • 06/25/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/20/2024 12:05:23 PM
- Tonix Pharmaceuticals Announces Positive Pre-NDA CMC Meeting with FDA for Tonmya™ for the Management of Fibromyalgia • GlobeNewswire Inc. • 06/20/2024 12:00:00 PM
- Tonix Pharmaceuticals Presented Data Comparing Real-World Treatment of Migraine with Industry Guidelines for Non-Oral Products at the Annual Scientific Meeting of the American Headache Society (AHS) • GlobeNewswire Inc. • 06/18/2024 12:00:00 PM
- Tonix Pharmaceuticals Presented Poster of Tonmya™ for the Management of Fibromyalgia at the Annual European Congress of Rheumatology (EULAR) 2024 • GlobeNewswire Inc. • 06/17/2024 12:00:00 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 06/14/2024 09:25:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/13/2024 09:24:27 PM
- Tonix Pharmaceuticals Announces Closing of $4.0 Million Public Offering • GlobeNewswire Inc. • 06/13/2024 09:00:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 06/12/2024 09:01:03 PM
- Tonix Pharmaceuticals Announces Pricing of $4.0 Million Public Offering • GlobeNewswire Inc. • 06/12/2024 01:00:00 PM
- Tonix Pharmaceuticals Announces Proposed Public Offering • GlobeNewswire Inc. • 06/11/2024 09:17:35 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 06/11/2024 08:49:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/10/2024 12:53:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/06/2024 03:21:23 PM
- Tonix Pharmaceuticals Announces 1-for-32 Reverse Stock Split • GlobeNewswire Inc. • 06/06/2024 03:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/06/2024 12:05:39 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM